The Columbus-based ophthalmic medical device company is developing new technologies for myopia, a common childhood vision condition that can progress as children grow. Myopia is influenced by both genetics and environment, including close-up visual behavior and reduced outdoor time. For children, that progression can mean more than stronger prescriptions. Over time, worsening myopia can increase risks for more serious eye health issues later in life.
Myoptechs began with soft contact lens technology and has completed an early clinical development plan that included four studies designed to identify the strongest prototypes for extended on-eye testing. The company has now expanded the technology into glasses, allowing Myoptechs to reach children who may be diagnosed earlier in life but are not yet ready for contact lenses.
That matters because, as CEO Paul Grimm says, “It’s tough to get a six- or seven-year-old to be compliant with contact lenses.” Glasses will allow the company to serve children earlier in their journey while contact lenses adds a different modality which may be more preferred as they age.
The company is building from a strong intellectual property foundation. Myoptechs holds a worldwide exclusive license to technology developed at The Ohio State University, by Dr. Tom Raasch. The Company has been granted two U.S. patents, a milestone Grimm describes as a welcome acceleration in a field where time is always a critical factor.
For Myoptechs, progress is happening across multiple fronts: Advancing contact lenses, moving glasses into clinical study, strengthening patent protection, and raising the capital required to move carefully through clinical development.
The work is exacting, but the benefit is easy to understand. When Myoptechs succeeds, more children can gain access to vision correction designed not only for how they see now, but for how their eyes develop over time.
Share this article:
Contact us today and discover how we can help propel your business forward.
